SG Americas Securities LLC Has $128,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID)

SG Americas Securities LLC raised its position in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 52.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 39,792 shares of the company’s stock after purchasing an additional 13,728 shares during the quarter. SG Americas Securities LLC’s holdings in Ovid Therapeutics were worth $128,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Ovid Therapeutics by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 3,687,909 shares of the company’s stock worth $11,580,000 after buying an additional 245,291 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Ovid Therapeutics by 369.5% during the 2nd quarter. BlackRock Inc. now owns 3,408,207 shares of the company’s stock worth $11,179,000 after buying an additional 2,682,320 shares in the last quarter. Madison Avenue Partners LP boosted its holdings in shares of Ovid Therapeutics by 95.2% during the 4th quarter. Madison Avenue Partners LP now owns 2,721,051 shares of the company’s stock worth $5,061,000 after buying an additional 1,327,029 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Ovid Therapeutics by 142.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,213,085 shares of the company’s stock worth $3,979,000 after buying an additional 713,450 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Ovid Therapeutics by 435.4% during the 2nd quarter. State Street Corp now owns 1,026,631 shares of the company’s stock worth $3,367,000 after buying an additional 834,898 shares in the last quarter. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Price Performance

Shares of OVID opened at $3.11 on Thursday. Ovid Therapeutics Inc. has a 12-month low of $2.57 and a 12-month high of $4.14. The business’s fifty day moving average is $3.27 and its 200 day moving average is $3.36. The company has a quick ratio of 9.55, a current ratio of 9.55 and a debt-to-equity ratio of 0.17. The stock has a market cap of $219.91 million, a P/E ratio of -4.15 and a beta of 0.71.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Friday, March 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Ovid Therapeutics had a negative return on equity of 49.76% and a negative net margin of 13,351.53%. The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. Sell-side analysts anticipate that Ovid Therapeutics Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on OVID. Wedbush began coverage on Ovid Therapeutics in a report on Friday, April 5th. They set an “outperform” rating and a $8.00 price target on the stock. BTIG Research began coverage on Ovid Therapeutics in a report on Thursday, December 21st. They set a “buy” rating and a $11.00 price target on the stock.

Insider Buying and Selling

In other news, CEO Jeremy M. Levin bought 18,248 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $50,364.48. Following the acquisition, the chief executive officer now directly owns 3,616,715 shares in the company, valued at $9,982,133.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.60% of the stock is owned by company insiders.

Ovid Therapeutics Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.